No More Waiting: 340B Drug Pricing Program Pharma Oversight and Enforcement Rule To Be Effective January 1, 2019

December 17, 2018 Alerts and Newsletters

The U.S. Department of Health and Human Services ("HHS") recently published a final rule on the 340B Drug Pricing Program ("340B Program"), moving the effective date for changes to the program up to January 1, 2019. Making the rule effective next month is welcome news for eligible hospitals, clinics, and health centers that serve vulnerable populations ("Covered Entities") because it establishes the methodologies for pharmaceutical manufacturers' 340B ceiling prices as well as establishes civil monetary penalties ("CMPs") for manufacturers that knowingly and intentionally charge Covered Entities more than the designated ceiling price. HHS is also planning on launching a website where Covered Entities may easily verify manufacturer pricing data to ensure that they are not being overcharged. The website is expected to open during the first quarter of 2019.


The 340B Program requires drug manufacturers who want to participate in Medicaid to provide outpatient drugs at a 20%-50% discount to Covered Entities. In January 2017, HHS published a final rule ("2017 Rule") in the Federal Registerin which it set forth the calculation of the 340B ceiling prices, created the penny pricing policy, and established CMPs. Now after eight years and five delays, each Covered Entity will be able to ensure that manufacturers are observing the drug price ceilings and HHS will be able to enforce them.

The 2017 Rule will apply to all drug manufacturers that are required to make their drugs available to Covered Entities under the 340B Program. Since Covered Entities get reimbursed from the government at a higher rate than what they are charged, the 340B Program plays an integral role in helping providers provide high-quality and low-cost care to patients that otherwise would not have the ability to pay for their care. Below, we highlight some of the key provisions from the 2017 Rule.

Ceiling Price

HHS receives both the average manufacturer price and unit rebate amount quarterly data from the Centers for Medicare & Medicaid Services to calculate the 340B ceiling price. Unfortunately, the Office of the Inspector General ("OIG") has found that drug manufacturers oftentimes do not accurately provide the required discounts to Covered Entities.
Created to discourage drug manufactures from raising prices faster than inflation, the penny pricing policy mandates a manufacturer to charge Covered Entities $0.01 per unit if the 340B ceiling price equals zero. An OIG report discovered drug manufacturers commonly overcharging Covered Entities for drugs that would be covered under the penny pricing policy. These Covered Entities paid an excess from $1.65 to $1,931 over the ceiling price.

Manufacturer CMPs

Drug manufacturers that knowingly and intentionally charge Covered Entities a price for a 340B drug that exceeds the price ceiling will face CMPs. The 2017 Rule directs drug manufacturers participating in the 340B Program to disclose the maximum per unit ceiling price that can be charged to 340B Covered Entities. Enforcement will be maintained through a closed website available to 340B participating providers. Federal regulators will post drug pricing information on the site.

Covered Entities Should be Vigilant

HHS has indicated that the ceiling price website will be launching soon. Hospitals and other Covered Entities are encouraged to follow the development of the online access and verify the ceiling prices they are charged by drug manufacturers to ensure that they are not being overcharged. Verrill Dana will continue to monitor and bring you updates on this matter.

For assistance with questions regarding the new implementation date, the 2017 Rule, or the 340B Program, please reach out to Gary Rosenberg or your regular Verrill Dana attorney.

Firm Highlights


Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...


FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...


38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...


Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...


EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...


Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...


News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...


European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...


FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...


Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.